CA2501663A1 - Stilbene derivatives having an immune-modulating activity - Google Patents

Stilbene derivatives having an immune-modulating activity Download PDF

Info

Publication number
CA2501663A1
CA2501663A1 CA002501663A CA2501663A CA2501663A1 CA 2501663 A1 CA2501663 A1 CA 2501663A1 CA 002501663 A CA002501663 A CA 002501663A CA 2501663 A CA2501663 A CA 2501663A CA 2501663 A1 CA2501663 A1 CA 2501663A1
Authority
CA
Canada
Prior art keywords
propylphenyl
dimethoxy
group
ethenyl
benzenediol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002501663A
Other languages
French (fr)
Inventor
Genhui Chen
Jianxiong Li
Wei Liu
John M. Webster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welichem Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2501663A1 publication Critical patent/CA2501663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C07C39/215—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring containing, e.g. diethylstilbestrol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings

Abstract

This invention provides a novel group of diphenyl ethene derivatives, pharmaceutically acceptable salts thereof, the process of making these compounds, their pharmaceutical composition and the use of these compounds a s agents for treating immune, inflammatory and auto-immune diseases.

Description

NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
Background of the Invention Stilbene derivatives are well-known in the art to have a wide range of activities and are widely distributed in nature. There is a growing interest in stilbene derivatives because of a range of activities that have been observed in some of the naturally occurring as well as some of the synthetic stilbenes. A
stilbene derivative, 3,5,4'-trihydroxystilbene, commonly known as resveratrol in which both isomers (cis or trans) has been reported to have a range of biological functions, such as mediating inflammation and cancer chemoprevention (Jang, et al. 1997, Science, 275, 218, US6,008,260).
It is known in the art that substitution on the various position on the two phenyl rings of the basic stilbene structure results in a great diversity of compounds, including those with one or two substituents on one or both of the phenyl rings of the stilbene structure(Shudo K., 1988, US4723028; Hensley, K.L., et al., WO99/59561, Kunihiro N., 1983, JP58159410; Genji L, 1995, JP07053359 and GB1465661) and those with three or more substituents on the phenyl rings (Koichi, S. et al., 1986, EP0170105; Shozo Y., et al., 1986, JP08337523; and Charpentier B. et al., 1992, W092/19583).
Compounds with other substitution on the phenyl ring, such as derivatives of vitamine A (Ney, U.M., et al. 1987, Dermatologica, 175:93-99) and vitamine D (WO 00/26167) are well-known in the art. Several publications (W092/16486, W099/40056, WO01/95859 and Cuslunan M. et. al. (1992, J. Med.
Chem., 35:2293-2306) disclosed compounds that are derived from 3, 4, 5-trimethoxyl stilbene.
These compounds showed anti-neoplastic activity and modest activity of modulating cytokines (WO01/95859).
Recently, a group of stilbenes with a unique substitute pattern of two hydroxyl groups, or their derivatives, in position 3 and 5 and a substituent in between have been disclosed. Pending applications of the inventors are directed to compounds having inhibitory activity against kinases, anti-inflammatory activity (WO 01/42231), having effect on T lymphocytes, macrophages, neutrophils and mast cells and modulating a variety of immune and inflammatory activities (WO 02/057219).
However, it is not discovered until now that with the unique substitution pattern on one phenyl group the substitution on the other phenyl group with a range of specific substituents, in particular fluoro atoms, resulted in compounds that have surprising immune-modulating activity. The present invention is related to these novel stilbene compounds, their synthesis, their unexpected activity, pharmaceutical composition and their use for treatment of disorders associated with these activities.

Summary of the Invention The invention disclosed herein relates to compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical composition of these compounds that have been found useful as immune-modulating agents.
R3~
R4 Rs R1 ~ ~ \ _ R2O ~ ~ R6 I
R8 R' Detailed Description of the Invention The invention covers new compounds of general formula I, R4 Rs R2O - ~ > ~ R6 1 R$ R' wherein R' is selected from the group consisting of unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, or COR9;
RZ and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl;
R4, R5, R6, R' and R$ are not H simultaneously and are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, CORD, NRl°R", S(O)ZN R'°Rll, S(O)"Rl°, n = 0-2, OR12, a cyclic, or a heterocyclic group; with the proviso that R~ is not hydroxy or alkyoxy group when R' is an unsaturated group comprising of 1-3 isoprene unit(s);
R9 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl, or NR'°R11, or ORIO;
Rl° and Rll are selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl;
R'z is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl.
In particular, new compounds of general formula I, wherein R4, R5, R6, R' and R8 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NRl°Rll, S(O)ZN
R'°RI1, S(O)"R'°, n = 0-2, OR12, a cyclic, or a heterocyclic group and one or more than one of R4, R5, R6, R' and R8 is F. The configuration of the double bond of the compound of formula I is E or ~.
Highly preferred compounds include the following:
4-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid (6).
3-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid (7).
5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol (13).
5-[2-(3,5-Dihydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol (15).
5-[2-(2-Fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (37).
5-[2-(3-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (38).
5-[2-(4-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (39).
5-[2-(3,5-Difluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (40).
5-[2-(2,4-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (41).
S-[2-(2,6-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (42).
2-i-Propyl-5-[2-(2,4,6-trifluorophenyl)ethenyl]-1,3-benzenediol (43).
5-[2-(2,3,4,5,6-Pentafluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (44).
The invention also covers use of the compounds of general formula I as immune-modulating agents.
The compounds of this invention may be synthesized using general procedures disclosed in patent publication W002/057219 with specific modifications. Examples given herein are illustrative only, and are not considered as limitations of this invention. In general, the stilbene structures of the compounds of the invention are constructed via Wittig olefination (Scheme 1) and Heck reaction (Scheme 2). The corresponding 1,3-benezendiol can be obtained by a deprotection reaction.
Scheme 1. Wittig olefination:
H O
-r- ~P(O)(OEt)2 R20 ~ 3 Ar OR
RI RIO
O Rl P(OEt)2 \ Ar II
'Ar R20 \ OR3 Scheme 2. Heck reaction:
i Pd-Cat R3O
R O ~ I 2 + ArBr RI
\OR 2 \ Ar RO
Scheme 3. Modification:

BuLi HO / \
R'CHO R' Rzo R3 Ar'B(OH~ ~,, / \
\ Ar ~r / \ ~ R2O
'-Ar RzO Rs0 BuLi OHC / \
DMF Rz0 Etc.
One modification of Rl is to start with a bromostilbene (Scheme 3). The bromide can be converted to other functional groups by Suzuki coupling or a bromo-lithium exchange followed by reacting with an electrophile.
The compounds utilized in accordance with the present invention have Z or E
configuration of the double bonds resulting in traps and cis isomers. The scope of the present invention is intended to cover all such isomers as well as mixtures of cis and traps isomers.
A pharmaceutically acceptable salt may be prepared for any compounds in this invention having a functional capability of forming such salt. Pharmaceutically acceptable salts may be formed with inorganic and/or organic acids and bases. Suitable acids include, for example, hydrochloric, sulfuric, nitric, benzenesulfonic, acetic, malefic, tartaric and the like, which are pharmaceutically acceptable.
While pharmaceutically acceptable salts are preferred, particularly when employing the compounds of the invention as medicaments, other salts find utility, for example, in the production of these compounds, or where non-medicament-type uses are contemplated.
Compounds of the present invention have shown a range of immune-modulating activities that are demonstrated and confirmed in the forthcoming examples. Compounds which have immune-modulating activity are well-known in the art, and are described in numerous patent and scientific publications. It is generally known and accepted in the art that immune-modulating activity is useful for treating numerous diseases and conditions of animals, including humans. It is generally known in the art that pharmaceuticals having a compound or compounds with immune-modulating activity, such as those disclosed herein, as the active ingredient are useful agents for the treatment of disorders such as: clinical transplants (such as organ transplant, acute transplant or heterograft or homograft (such as is employed in burn treatment)) rejection; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes;
transplantation tolerance induction; arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis; inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosis); graft vs. host disease; T-cell mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenalglands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia;
vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases;
glomerulonephritis, serum sickness; uticaria; allergic diseases such as respiratory allergies (asthma, hay fever, allergic rhinitis) or skin allergies; scleracierma; mycosis fungoides; acute inflammatory responses (such as acute respiratory distress syndrome and ishchemia/reperfusion injury); dennatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis palmoplanteris; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic schlerosis; and morphea. In particular, the activity against VEGF
expression finds utility in treating cancers and VEGF associated disorders.
The inhibition of LTBd induced cell migration is useful as anti-inflammatory agents.
The present invention thus provides methods for the treatment of disorders associated with the abovementioned activities, comprising the step of administering to a subject in need thereof at least one compound of the formula I in an amount effective therefore. Other therapeutic agents such as those known to the skilled in the art may be employed with the inventive compounds in the present methods. W
the methods of the present invention, such other therapeutic agents) may be administered prior to, simultaneously with or following the administration of the compounds) of the present invention.
Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules, powder, suppositories etc.) or liquid (solutions, suspensions or emulsions) in a suitable composition for oral, topical, parenteral or rectal administration. These formulations may contain the pure compound or be in combination with a carrier or some other pharmaceutically active compound. These compositions may need to be sterile when administered parenterally.
For topical use, it will be preferred to use in the form of creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I (For purposes of this application, topical application shall include mouth washes and gargles.) Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to about 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of -S-active agent compounded with an appropriate and convenient amount of carrier material that may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 50,0 mg, 600 mg, 800 mg, or 1000 mg.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
The invention is now described in greater detail by reference to the following non-limiting examples.
Synthesis of compounds Example 1. 4-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid (1).
a). Methyl 3,5-dimethoxy-4-i-propylbenzoate.
This compound was obtained using method described in WO 01/42231. 1HNMR
(CDC13, ppm): b 1.32 (d, J = 7.2 Hz, 6H), 3.66 (hept, J = 7.2 Hz, 1H), 3.82 (s, 6H), 3.95 (s, 3H), 7.25 (s, 2H).
b). 3,5-Dimethoxy-4-i-propylbenzyl alcohol.
To a suspension of LiAlH4 (95%) (S.OOg, 125mmol) in dry ether (100mL) at 0°C was added a solution of methyl 3,5-dimethoxy-4-i-propylbenzoate (15.7g, 90.1mmo1), in ether (300mL) under Nz.
The suspension was stirred at 0°C for one hour then for an additional hour at room temperature. The reaction was quenched by slow addition of a saturated Na2S04 aqueous solution (1 OmL) at 0°C. The mixture was stirred overnight. The solid was filtered off and the filtrate was evaporated to dryness to give the desired alcohol (13.8g, 88% yield) as white crystals. IHNMR (CDCl3.
ppm): 8 1.34 (d, J =
7.2Hz, 6H), 3.65 (kept., J = 7.2Hz, 1H), 3.88 (s, 6H), 4.70 (s, 2H), 6.62 (s, 2H).
c). 3,5-Dimethoxy-4-i-propylbenzyl aldehyde.
A mixture of 3,5-dimethoxy-4-i-propylbenzyl alcohol (13.OSg, 62.lmmol) and pyridinium chlorochromate (33.92g, 157mmo1) was stirred in CHzCl2 (100mL) in the presence of KzCO3 (4.18g, 30mmo1) for 30 min. Ether (300mL) was added to quench the reaction. The mixture was passed through a short pad of Florisil and the pad was washed thoroughly with ether.
Evaporation of the solvent gave 3,5-dimethoxy-4-i-propylbenzyl aldehyde (11.89g. 92% yield) as a yellowish crystal.
1HNMR (CDCl3, ppm): ~ 1.32 (d, J = 7.2Hz, 6H), 3.68 (hept., J = 7.2Hz, 1H), 3.92 (s, 6H), 7.12 (s, 2H), 9.96 (s, 1H).
d). (3,5-Dimethoxy-4-i-propylphenyl)ethene.
To a suspension of methyltriphenylphosphonium bromide (6.89g, 19.3mmo1) in THF
(100mL) under argon was added BuLi (7.7m1, 2.5M in hexane, 19.3mmol) at room temperature.
The resultant red solution was stirred for 10 min. and then 3,5-dimethoxy-4-i-propylbenzyl aldehyde (4.02g, 19.3mmo1) in THF (20mL) was added. After 2 hours, the reaction was quenched with water (20mL). The mixture was extracted with ether (3 x 100mL). The extract was washed with saturated saline solution (3 x 30mL) and dried over sodium sulphate. Evaporation of ether followed by flash chromatography using 3% ethyl acetate in hexane afforded pure (3,5-dimethoxy-4-i-propylphenyl)ethene (2.64g, 66%
yield) as a colorless solid. II~IMR (CDCl3, ppm): 8 1.31 (d, J = 7.lHz, 6H), 3.61 (qint, J = 7.lHz, 1H), 3.86 (s, 6H), 5.25 (d, J = llHz, 1H), 5.73 (d, J = l7Hz, 1H), 6.64 (s, 2H), 6.70 (dd, J = 11, l7Hz, 1H).
e). 4-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid (1).
A mixture of (3,5-dimethoxy-4-i-propylphenyl)ethene (0.303g, l.SOmmol), 4-bromobenzoic acid (0.269g, 1.30mmol), dihydrogen di-p.-chlorotetrkis(di-test-butylphosphinito-xP)dipalladate (0.0625g, 0.067mmol), Bu4NI (0.245g, 0.67mmo1) and KzC03 (0.614g, 4.40mmol) in DMF (7mL) was heated at 140°C under argon. After the reaction was complete (Sh), the reaction mixture was poured into water (100m1). This was washed with ether. The aqueous phase was acidified with 6NHCl and extracted with ether (2 X100mL). The extract was washed with saturated sodium chloride and then dried over anhydrous Na2SO4. Evaporation of ether gave the pure acid 1 (0.345g, 71% yield). 1~INMR
(CDCl3, ppm): S 1.32 (d, J = 7.lHz, 6H), 3.63 (qint, J = 7.lHz, 1H), 3.90 (s, 6H),6.76 (s, 2H), 7.08 (d, J = l7Hz, 1H), 7.27 (d, J = l7Hz, 1H), 7.63 (d, J = 8Hz, 2H), 8.13 (d, J =
8Hz, 2H).
Example 2. 3-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid (2).
This compound was synthesized from (3,5-dimethoxy-4-i-propylphenyl)ethene and 3-bromobenzoic acid in 77% yield in the same way as described in preparation of 1. 1HNMR
(CDCl3, ppm): 8 1.32 (d, J = 7.lHz, 6H), 3.63 (qint, J = 7.lHz, 1H), 3.90 (s, 6H), 6.76 (s, 6H), 7.08 (d, J = l7Hz, 1H), 7.25 (d, J = l7Hz, 1H), 7.50 (t, J = 7.7Hz, 1H), 7.79 (d, J = 7.7Hz, 1H), 8.04 (d, J =
7.7Hz, 1H), 8.31 (s, 1H).
Example 3. 4-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid (6).
A mixture of 4-[2-(3.5-dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid (0.289g, 0.886mmol) and pyridine hydrochloride (0.678, 5.9 mmol) was heated at 200°C for 2 h under a stream of argon. The reaction mixture was cooled to room temperature. 2NHC1 (IOmL) and ether (SOmL) was added. The organic layer was separated and the aqueous mixture was extracted with ether (2 x SOmL). The extract was washed with saturated brine and dried over anhydrous NaaS04.
Evaporation of ether followed by flash chromatography using ethyl acetate/hexane/acetic acid (40/60/1) afforded the pure acid 6 (0.03g, 11% yield).'HNMR (DMSO-d6, ppm): 8 1.22 (d, J = 7.OHz), 6.49 (s, 2H), 6.90 (d, J =
l8Hz, 1H), 7.19 (d, J = l8Hz, 1H), 7.67 (d, J = 8Hz, 2H), 7.90 (d, J = 8Hz, 2H), 9.14 (s, 2H).
Example 4. 3-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid (7).
This material was prepared from 3-[2-(3.5-dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid 2 and pyridine hydrochloride in 86% yield in the same way as described in example 3.
'I~~1MR (DMSO-d6, ppm): 8 1.22 (d, J = 7.OHz, 6H),6.48 (s, 2H), 7.03 (d, J = l7Hz, 1H), 7.12 (d, J = l7Hz, 1H), 7.46 (t, J
= 7.SHz, 1H), 7.7-7.9 (m, 2H), 8.06 (s, 1H), 9.12 (s, 2H).
Example 5. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-phenylethene (19).
a). Diethyl benzylphosphonate.
The mixture of benzyl bromide (l2mL, lOlmmol) and triethyl phosphite (25mL, 146mmol) was heated at 110-130°C in the presence of Bu4NI (O.OSg) overnight. The excess triethyl phosphite was _7_ removed under reduced pressure at 110°C. The phosphonate (23g) was obtained quantitatively as a colorless liquid. 1HNMR (CDC13, ppm): 8 1.28 (t, J = 7.2Hz, 6H), 3.20 (d, J =
21.9Hz, 2H), 4.10 (dt., J = 7.2Hz, 7.2Hz, 4H), 7.30 (s, SH).
b). 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-phenylethene (19).
To a solution of diethyl benzylphosphonate obtained above (11.39g, 54.7mmol) in THF (100mL) at 0°C was added NaH (60% in mineral oil) (4.68g, 115mmol) under N2. After the addition was completed, the suspension was stirred at 0°C for 1 h and 3,5-dimethoxy-4-i-propylbenzyl aldehyde obtained in example 1(c) (11.39g, 54.7 mmol) in THF (100mL) was added. The reaction was kept at 0°C for 1 h and then at ,45-50°C for 5 h. The reaction was cooled to 0°C. Water was added slowly to quench the reaction followed by addition of 2N HCl (75mL). The mixture was extracted with ether (3 ae 200mL). The extract was dried over anhydrous NazSOd. Evaporation of ether gave crude 5-(2-phenylethenyl)-2-i-propyl-1,3-dimethoxy benzene (18.07g). This was used for the next reaction without further purification. A small amount of the crude product was purified by flash chromatography using 10% ethyl acetate in hexane to afford pure product.'HNMR
(CDC13, ppm): 8 1.28 (d, J= 7.0 Hz, 6H), 3.58 (hept, J= 7.0 Hz, 1 H), 3.85 (s, 6 H), 6.69 (s, 2 H), 7.05 (s, 2 H), 7.25 (m, 1 H), 7.3 5 (m, 2 H), 7.25 (m, H).
Example 6. 5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol (20).
To the crude 1-(3,5-dimethoxy-4-i-propylphenyl)-2-phenylethene (18.07g) in dry CHZC12 (100mL) at -78°C under NZ was added BBr3 (5.2mL, SSmmol) dropwise. After the reaction was stirred at -78°C
for 1 h, the temperature was allowed to rise to room temperature and the reaction mixture was stirred at room temperature for 2 days. Water was added to quench the reaction, followed by 20% NaOH to adjust pH > 12. The organic layer was removed and the aqueous layer was washed with hexane (2 x 100mL). The aqueous layer was acidified with 6N HCl to pH 1 and extracted with ether (3 x 200mL).
The organic layer was separated and washed with water (SOmL) and brine (SOmL) and dried over anhydrous Na2SO4. Evaporation of ether gave a red syrup. Recrystallization with chloroform yielded pure stilbene product 20 (6.92g) as a white' crystal. The mother liquid was concentrated and the residue was recrystallized once more to afford an additional 2.Sg of 20 (total 9.42g, 67.7% over two steps).'HNMR (CDCl3, ppm): 8 1.38 (d, J = 7.3Hz, 6H), 3.46 (kept., J = 7.3Hz, 1H), 4.80 (s, 2H), 6.50 (s, 2H), 6.92 (d, J = 17.2Hz, 1H), 6.97 (d, J = 17.2Hz, 1H), 7.25 (m, 1H), 7.34 (m, 2H), 7.52 (m, 2H).
Example 7. 3-Acetoxy-5-(2-phenylethenyl)-2-i-propylphenyl acetate (10).
To 5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol obtained in example 11 (l.OOg, 3.93mmol) and triethylamine (l.SmL, 10.8mmol) in dichloromethane (100mL) at 0°C was added acetyl chloride dropwise. The reaction was monitored by TLC. Water (SOmL) was added after the reaction was complete (~30 min.). The organic layer was separated and washed with 2NHCl (30mL), H20 (SOmL), saturated NaHC03 (SOmL), H20 (SOmL) and brine (SOmL), and dried over anhydrous sodium sulfate.
Evaporation of the solution followed by flash chromatography using 5% ethyl acetate in hexane _g_ yielded 3-acetoxy-5-(2-phenylethenyl)-2-i-propylphenyl acetate. (1.32g, 92%) as a white solid.
'HNMR (CDC13, ppm): 8 1.26 (d, J = 7.OHz, 6H), 2.35 (s, 6H), 3.08 (hept., J =
7.OHz, 1H), 6.98 (d, J
=17.4Hz, 1H), 7.04 (d, J = 17.4Hz, 1H), 7.07 (s, 2H), 7.24-7.29 (m, 1H), 7.34-7.38 (m, 2H), 7.45-7.49 (m, 2H).
Example 8. 3-Chloroacetoxy-5-(2-phenylethenyl)-2-i-propylphenyl chloroacetate(11).
This material was synthesized from anhydrous chloroacetic and 5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol obtained in example 11 in 72%yield by the same procedure as described in example 12.
'HNMR (CDC13, ppm): b 1.30 (d, J = 7.OHz, 6H), 3.08 (hept, J=7.OHz, 1H), 4.39 (s, 4H), 6.96 (d, J =
l7Hz, 1H), 7.14 (d, J = l7Hz, 1H) 7.17 (s, 2 H), 7.2-7.5 (m, 5 H).
Example 9. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethene (12).
a). 3,5-Dimethoxy-4-isopropyl benzyl bromide To 3,5-Dimethoxy-4-i-propylbenzyl alcohol (12.57g, 59.8mmo1) in dry ether (100mL) at 0°C was added PBr3 (3.OmL, 31.2mmo1) dropwise under nitrogen. The reaction was monitored by TLC. After the reaction was completed (~4h), water (180mL) was added. The organic layer was separated and the aqueous layer was extracted with ether (3 ae SOmL). The extract was washed with water (20mL), sat. NazC03 (20mL), water (20mL) and brine (20mL), and dried over anhydrous sodium sulfate.
Evaporation of the solution yielded pure bromide (14.93g, 91.4%) as a white solid.'HNMR (CDC13, ppm): 8 1.29 (d, J = 7.lHz, 6H), 3.64 (hept, J = 7.lHz, 1H), 3.84 (s, 6H), 4.50 (s, 2H), 6.60 (s, 2H).
b). Diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate.
The mixture of 3,5-dimethoxy-4-i-propylbenzyl bromide (S.Olg, 18.3mmol) and triethyl phosphite (4.7mL, 27.4mmo1) was heated at 110-130°C in the presence of BudNI
(O.OSg) overnight. The excess triethyl phosphite was removed under reduced pressure at 110°C to give the phosphonate (5.58g, 92%). 1HNMR (CDC13, ppm): h 1.27 (d, J = 7. lHz, 6H), 1.29 (t, J = 7.OHz, 6H), 3.12 (d, J =2l.SHz, 2H), 3.4-3.7 (m, 1H), 3.80 (s, 6H), 4.06 (dt, J =7.1, 7.lHz, 4H), 6.50 (d, J =
2.6Hz, 2H).
c). 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethene (12).
This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate and 4-anisaldehyde in 63% yield as the same procedure as described in example 5(b).'HNMR (CDC13, ppm): 8 1.31 (d, J=7.lHz, 6H), 3.51-3.74 (m, 1H), 3.86 (s, 3H), 3.91 (s, 6H), 6.71 (s, 2H), 6.84-7.09 (m, 4H), 7.39-7.60 (m, 2H).
Example 10. 5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol (13).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethene and pyridine hydrochloride in 30% yield in the same way as described in example 3.
'H NMR (DMSO-d6, ppm): 8 1.22 (d, J=7.OHz, 6H), 3.41 (m, 1H), 6.40 (s, 2H), 6.73 (d, J = 6.3Hz, 4H), 7.33 (s, 1H), 7.41 (s, 1H), 8.98 (s, 2H), 9.51 (s, 1H).
Example 11. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3,5-dimethoxyphenyl)ethene (14).
This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate and 3,5-dimethoxybenzaldehyde in 25%yield as the same procedure as described in example 5(b) _g_ Example 12. 5-[2-(3,5-Dihydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol (15).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(3,5-dimethoxyphenyl)ethene and BBr3 by the same procedure as described in example 11.
Example 13. 1-(4-Bromo-3,5-dimethoxyphenyl)-2-phenylethene (21).
a). Methyl 4-bromo-3,5-dimethoxybenzoate.
This material was synthesized from 4-bromo-3,5-dihydroxybenzoic acid and MeaS04 in 95% yield by the same method as described in example 1 (a). 1HNMR (CDCl3, ppm): 8 3.96 (s, 3 H), 3.99 (s, 6 H), 7.28 (s, 2 H).
b). 4-Bromo-3,5-dimethoxybenzyl alcohol.
This material was synthesized from methyl 4-bromo-3,5-dimethoxybenzoate obtained above in 85%
yield by the same method as described in example 1(b). IHNMR (CDCl3, ppm):
81.95 (s, 1H), 3.93 (s, 6H), 4.69 (s, 2H), 6.61 (s, 2H).
c). 4-Bromo-3,5-dimethoxybenzaldehyde.
This material was synthesized from 4-bromo-3,5-dimethoxybenzyl alcohol in 75%
yield by the same method as described in example 1(c). ~HNMR (CDCl3, ppm): 8 4.02 (s, 6 H). 7.11 (s, 2H), 9.97 (s, 1 H).
d). 1-(4-Bromo-3,5-dimethoxyphenyl)-2-phenylethene (21).
This material was synthesized from 4-bromo-3,5-dimethoxybenzyl aldehyde and diethyl benzylphosphonate in 70% yield by the same method as described in example 5(b).'HNMR (CDCl3, ppm): S 3.96 (s, 6 H), 6.72 (s, 2 H), 7.06 (d, J = l7Hz, 1H), 7.11 (d, J =
l7Hz, 1H), 7.28 (m, 1 H), 7.3 7 (m, 2 H), 7.5 5 (m, 2 H).
Example 14. 2-Bromo-5-(2-phenylethenyl)-1,3-benzenediol (22).
This material was synthesized from 1-(4-bromo-3,5-dimethoxyphenyl)-2-phenylethene (21) and BBr3 in 90% yield by the same method as described iii example 6. 1HNMR (CDCl3, ppm): ~ 5.39 (s, 2H), 6.81 (s, 2H), 7.06 (d, J = l7Hz, 1H), 7.11 (d, J = l7Hz, 1H), 7.28 (m, 1H), 7.37 (m, 2H), 7.55 (m, 2H).
Example 15. 1-[2,5-Dimethoxy-4-(2-phenylethenyl)]phenyl-1-phenylmethanol (16).
To a solution of 1-(4-bromo-3,5-dimethoxyphenyl)-2-phenylethene (0.2185g.
0.6845mmol) in dry THF (lOmL) at-78°C was added BuLi (0.3mL, 2.SM in hexane, 0.7530mmol).
One hour after the addition, benzaldehyde (0.07mL, 0.69mmo1) was added. The reaction mixture was stirred at -78°C
for another 4 hours and then water (l2mL) was added to quench the reaction.
This was extracted with ether (3 x 20mL). The extract were combined and dried over anhydrous NaaS04.
Evaporation of solvent followed by flash chromatography using 5% ethyl acetate in hexane afforded pure 16 (0.203, 86% yield) as a yellow solid. The 1HNMR (CDCl3, ppm): S 3.88 (s, 6H), 4.26 (d, J = 5.6Hz, 1H),6.40 (br, 1H), 6.79 (s, 2H), 7.12 (s, 2H), 7.2-7.6 (m, lOH).
Example 16. 2,5-Dimethoxy-4-(2-phenylethenyl) benzaldehyde (17).
This compound was synthesized from 1-(4-bromo-3,5-dimethoxyphenyl)-2-phenylethene, BuLi and N,N-dimethylformamide in 38% yield by the same method as described in example 15. I~

(CDC13, ppm): S 3.9'4 (s, 3H), 4.00 (s, 3H), 6.75 (s, 2H), 7.14 (s, 2H), 7.3-7.5 (m, SH), 10.52 (s, 1H).
Example 17. 1-(3,5-Dimethoxy-4-ethylphenyl)-2-phenylethene (23).
To a solution of 1-(4-bromo-3,5-dimethoxyphenyl)-2-phenylethene (0.53g, l.7mmo1) in THF (lOmL) was added t-Butyl Li (1.1 mL, 1M in THF) at - 78 °C. After the addition complete, the solution was slowly heated to reflux for 30 min and then cooled down to - 78 °C.
Ethyl iodide (1.2 eq, 0.27 mL) was added to the solution. Water (1 OmL) was added after the completion of the reaction. THF was evaporated and the mixture was extracted with CHZC12 (3 x 5 mL). The extract was combined and dried over anhydrous magnesium sulfate. Evaporation of the solution followed by flash chromatography using 20% ether in hexane gave 1,3-dimethoxy-2-ethyl-5-(2-phenylethenyl)benzene in 70% yield. IHNMR (CDC13, ppm): 8 1.12 (t, J= 7.2 Hz, 6H), 2.70 (q, J= 7.2 Hz, 2H), 3.91 (s, 6H), 6.74 (s, 2H), 7.07 (s, 2 H), 7.26 (m, 1H), 7.36 (m, 2H'), 7.52 (m, 2 H).
Example 18. 2-Ethyl-5-(2-phenylethenyl)-1,3-benzenediol (24).
This material was synthesized from 1-(3,5-dimethoxy-4-ethylphenyl)-2-phenylethene and BBr3 in 91% yield by the same method as described in example 6. 1HNMR (CDC13, ppm): S
1.22 (t, J= 7.SHz, 6H), 2.70 (q, J= 7.SHz, 2H), 4.81 (s, 2H), 6.60 (s, 2H), 7.00 (s, 2H), 7.26 (m, 1H), 7.36 (m, 2H), 7.52 (m, 2H).
Example 19. 1-(3,5-Dimethoxy-4-n-tetradecanylphenyl)-2-phenylethene (25).
This material was prepared from 2-bromo-1,3-dimethoxy-5-(2-phenylethenyl)benzene and 1-bromo-n-tetradecane by the same procedure as described in example 15. 1HNMR (CDCl3, ppm): 8 0.91 (m, 6H), 1.29 (m, 22 H), 2.65 (m, 2H), 3.90 (s, 6H), 6.73 (s, 2H), 7.10 (s, 2H), 7.26 (m, 1H), 7.36 (m, 2H), 7.52 (m, 2H).
Example 20. 5-(2-Phenylethenyl)-2-n-tetradecanyl-1,3-benzenediol (26).
This material was synthesized from 1-(3,5-dimethoxy-4-n-tetradecanylphenyl)-2-phenylethene and BBr3 by the same method as described in example 6.'HNMR (CDC13, ppm): b 0.95 (m, 6H), 1.30 (m, 22H), 2.65 (m, 2H), 4.80 (s, 2H), 6.60 (s, 2H), 7.00 (s, 2H), 7.26 (m, 1H), 7.36 (m, 2H), 7.52 (m, 2H).
Example 21. 2-(3,5-Dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethene (27).
To a solution of diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate (O.SOg, l.Smmol) in THF
(IOmL) at 0°C was added NaH (60% in mineral oil) (0.14g, 3.Smmo1) under N2. After the addition was completed, the suspension was stirred at 0°C for 1 h and then 2-fluorobenzaldehyde (0.2mL, 1.9 mmol) in THF (lOmL) was added. The reaction was kept at 0°C for 1 h and then at 50°C for Sh. The reaction was cooled to 0°C. Water (SmL) was added slowly to quench the reaction followed by addition of 2N HCl (8mL). The mixture was extracted with ether (3 x 20mL). The extract was dried over anhydrous NazS04. Evaporation of ether followed by flash chromatography using 5% ethyl acetate in hexane as eluent afforded 2-(3,5-dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethene (1).
(0.31 g, 68%) as a yellow crystal. 1HNMR (CDC13, ppm): 8 1.34 (d, J = 7.lHz, 6H), 3.60 (qint. J=
7.lHz, 1H), 3.89 (s, 6H), 6.74 (s, 2H), 7.0-7.2 (m, SH), 7.4-7.6 (m, 1H).

Example 22. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3-fluorophenyl)ethene (28).
This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate and 3-fluorobenzaldehyde in the same way as described in example 21.
Example 23. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-fluorophenyl)ethene (29).
This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate and 4-fluorobenzaldehyde in the same procedure as described in example 21.
Example 24. 2-(3,5-Difluorophenyl)-1-(3,5-dimethoxy-4-i-propylphenyl)ethene (30).
This material was prepared from (3,5-dimethoxy-4-i-propylbenzyl)phosphonate and 3,5-difluorobenzaldehyde in 27% yield in the same way as described in example 21.
1HNMIZR (CDC13, ppm): 8 1.32 (d, J = 7.OHz, 6H), 3.66 (qint., J = 7.OHz, 1H), 3.90 (s, 6H), 6.72 (s, 2H), 6.8-7.2 (m, SH).
Example 25. 1-(2,4-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene (31) (3,5-Dimethoxy-4-i-propylphenyl)ethane.
To a suspension of methyltriphenylphosphonium bromide (6.89g, 19.3mmol) in THF
(100mL) under argon was added BuLi (7.7m1, 2.SM in hexane, 19.3mmol) at room temperature.
The resultant red solution was stirred for 10 min. and then 3,S-dimethoxy-4-i-propylbenzylaldehyde (4.02g, 19.3mmol) obtained above in THF (20mL) was added. After 2 hours, the reaction was quenched with water (20mL). The mixture was extracted with ether (3 x 100mL). The extract was washed with saturated saline solution (3 x 30mL) and dried over sodium sulphate. Evaporation of ether followed by flash chromatography using 3% ethyl acetate in hexane afforded pure (3,5-dimethoxy-4-i-propylphenyl)ethene (2.64g, 66% yield) as a colorless solid.'HNMR (CDCl3, ppm): S 1.31 (d, J =
7.lHz, 6H), 3.61 (qint, J = 7.lHz, 1H), 3.86 (s, 6H), 5.25 (d, J = llHz, 1H), 5.73 (d, J = l7Hz, 1H), 6.64 (s, 2H), 6.70 (dd, J = 1 l, l7Hz, 1H).
A mixture of (3,5-dimethoxy-4-i-propylphenyl)ethene (0.649g, 3.15mmol), 1-bromo-2,4-diflurobenzene (1.23g, 6.37mmol), dihydrogen di-p,-chlorotetrkis(di-tart-butylphosphinito-~cP)dipalladate (0.1409g, 0.151mmol), Bu4NI (0.582g, 1.58mmol) and I~ZC03 (1.45g, 10.5mmo1) in DMF (lOmL) was heated at 140°C under argon. After the reaction was complete (6h), the reaction mixture was poured into water (lOml).. The aqueous was acidified with 2NHCl and extracted with ether (2 X SOmL). The extract was washed with saturated sodium chloride and then dried over anhydrous NazS04. Evaporation of ether followed by flash chromatography using 2% ethyl acetate in hexane afforded 1-(2;4-difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene (31) quantitatively as a yellowish crystal. II~IMR (CDC13, ppm): 8 1.32 (d, J =
7.lHz, 6H), 3.63 (qint, J =
7.lHz, 1H), 3.90 (s, 6H), 6.76 (s, 2H), 7.08 (d, J = l7Hz, 1H), 7.27 (d, J =
l7Hz, 1H), 7.63 (d, J =
BHz, 2H), 8.13 (d, J = 8Hz, 2H).
Example 26. 1-(2,6-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene (32).
This compound was synthesized from (3,5-dimethoxy-4-i-propylphenyl)ethene and 1-bromo-2,6-diflurobenzene quantitatively in the same procedure as described in preparation of 31. II~IMR

(CDC13, ppm): 8 1.32 (d, J = 7.lHz, 6H), 3.62 (qint, J = 7.lHz, 1H), 3.90 (s, 6H), 6.73 (s, 2H), 6.8-7.2 (m, 4H), 7.41 (d, J = 16.6Hz, 1H).
Example 27. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,4,6-trifluorophenyl)ethene (33).
This compound was synthesized from (3,5-dimethoxy-4-i-propylphenyl)ethene and 1-bromo-2,4,6-triflurobenzene in 58% yield in the same procedure as described in preparation of 31. 1HNMR (CDC13, ppm): 8 1.32 (d, J = 7.OHz, 6H), 3.62 (qint, J = 7.lHz, 1H), 3.89 (s, 6H), 6.73 (s, 2H), 6.79-7.55 (m, 4H).
Example 28. 1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,3,4,5,6-pentafluorophenyl)ethene (34).
This compound was synthesized from (3~5-dimethoxy-4-i-propylphenyl)ethene and 1-bromo-2,3,4,5,6-triflurobenzene in the same procedure as described in preparation of 31.
Example 29. 5-[2-(2-Fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (37).
A mixture of 2-(3,5-dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethene (27) (0.308g, 1.03mmol) and pyridine hydrochloride (0.72g, 6.2 mmol) was heated at 200°C for 4 h under a stream of argon.
The reaction mixture was cooled to room temperature. 2NHC1 (lOmL) and ether (lSmL) was added.
The organic layer was separated and the aqueous layer was extracted with ether (3 ae 1 OmL). The extract was dried over anhydrous NazS04. Evaporation of ether followed by flash chromatography using 15% ethyl acetate in hexane afforded pure 5-[2-(2-fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (37) (0.269g, 95% yield) as an off white solid. 1HNMR (CDCl3, ppm): 8 1.41 (d, J =
7.2Hz, 6H), 3.51 (qint., J = 7.2Hz, 1H), 5.01 (b, 2H), 6.56 (s, 2H), 6.98 (d, J = 17.6Hz, 1H), 7.0-7.3 (m, 4H), 7.60 (ddd, J = 7.5, 7. S, 2.2Hz, 1 H).
Example 30. 5-[2-(3-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (38).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(3-fluorophenyl)ethene (28) and pyridine hydrochloride in the same procedure as described in example 34.
1HNMR (CDC13, ppm):
8 1.41 (d, 7.2Hz, 6H), 3.49 (qint., J = 7.2Hz, 1H), 6.53 (s, 2H), 6.9-7.5 (m, 6H).
Example 31. 5-[2-(4-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (39).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(4-fluorophenyl)ethene 29 and pyridine hydrochloride (38% yield over 2 steps) in the same procedure as described in example 34. IHNMR (CDCl3, ppm): 8 1.41 (d, 7.2Hz, 6H), 3.48 (qint., J = 7.2Hz, 1H), 6.52 (s, 2H), 6.81 (d, J
= l7Hz, 1H), 7.00 (d, J = l7Hz, 1H), 7.0-7.2 (m, 2H), 7.4-7.6 (m, 2H); 1HNMR
(DMSO-d6, ppm): b 1.22 (d, J = 7.lHz, 6H), 3.35 (qint., J = 7.lHz, 1H), 6.45 (s, 2H), 6.81 (d, J
= 16.7Hz, 1H), 6.99 (d, J =
16.7Hz, 1 H), 7.17 (dd, J = 8.8, 8.8Hz, 2H), 7.61 (dd, J = 8.8Hz, 5.6Hz, 2H), 9.05 (s, 2H).
Example 32. 5-[2-(3,5-Difluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol (40).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(3,5-difluorophenyl)ethene and pyridine hydrochloride in 70% yield in the same procedure as described in example 34. 1HNMR
(CDC13, ppm): 8 1.40 (d, J = 7.lHz, 6H), 3.56 (qint., J = 7.2Hz, 1H), 4.90 (s, 2H), 6.52 (s, 2H), 6.2-7.1 (m, SH).
Example 33. 5-[2-(2,4-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (41).

This material was prepared from 1-(2,4-difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene and pyridine hydrochloride in 44% yield in the same way as described in example 34, II~lMR
(CDC13, ppm): ~ 1.41 (d, J=7.lHz, 6H), 3.49 (qint, J = 7.lHz, 1H), 4.78 (br, 2H), 6.54 (s, 2H), 6.69-7.02 (m, 3H), 7.13 (d, J=l6Hz, 1H), 7.41-7.75 (m, 1H).
Example 34. 5-[2-(2,6-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (42).
This material was prepared from 1-(2,6-difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene and pyridine hydrochloride in 29% yield in the same way as described in example 34. IHI~tMR
(CDCl3, ppm): S 1.42 (d, J = 7.lHz, 6H), 3.50 (qint, J= 7.lHz, 1H), 4.77 (br, 2H), 6.57 ( s, 2H), 6.8-7.4 (m, SH).
Example 35. 2-i-Propyl-5-[2-(2,4,6-trifluorophenyl)ethenyl]-1,3-benzenediol (43).
This material was prepared from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-(2,4,6-trifluorophenyl)ethene and pyridine hydrochloride in 14% yield in the same way as described in example 29. 1FINMR
(CDC13, ppm): b 1.42 (d, J=7.lHz, 6H), 3.50 (qint, J = 7.lHz, 1H), 4.77 (br, 2H), 6.55 (s, 2H), 6.59-7.24 (m, 4H).
Example 36. 5-[2-(2,3,4,5,6-Pentafluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol (44).
This material was prepared from 1-(2,3,4,5,6-pentafluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethene and pyridine hydrochloride in 21% yield in the same way as described in example 34. 1HNMR (CDC13, ppm): b 1.40 (d, J=7.2Hz, 6H), 3.53 (d, J=7.2Hz, 6H), 4.91 (s, 2H), 6.55 (s, 2H), 6.86 (d, J = l7Hz, 1H), 7.28 (d, J = l7Hz, 1H).
The standard pharmacological procedures, described fully in the examples hereafter, show the compounds of the invention to inhibit T-cell, keratinocyte proliferation, cell migration induced by leukotriene B4 and to inhibit IFN-y secretion and VEGF expression ih vitr~o as well as to inhibit TNF-oc and edema ih vivo.
Example 37. Biological activity of novel compounds.
These assays for the following biological activities are well-established and known in the art, brief descriptions are provided herein for clarity.
(a). Effect on proliferation and IFN-y production of human peripheral blood mononuclear cells (PBMC) stimulated by phytochemagglutinin (PHA).
Experiment:PBMC were cultured with PHA and cultured with titrated concentrations of compounds or solvent, or media alone using standard cell culture techniques. The MTT
assay was performed after 48 hours of culture. Supernatants were collected after 48 hours of culture and levels of IFN-y were assayed by ELISA.
Results: 5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol (13) of the present invention had an ICSO of 2.97 against human PBMC proliferation while resveratrol had an ICSO of > 50.
Compound 13 is 20 times more potent in inhibiting PBMC proliferation (Table 1). Similarly, compound 13 is more than 15 times more potent than is resveratrol in inhibition IFN-y production (Table 2). Similarly, the three fluorinated compounds, 37, 38 and 39 had ICso < 10 ~M whereas that of resveratrol was > 50 ~M the highest concentration tested. The fluorinated compounds had superior activity in inhibiting PBMC proliferation to that of resveratrol with >5 times more potency (Table 1).
Similarly, the ICso value of resveratrol is more than 9 times higher than that of the three fluorinated compounds, indicating that the fluorinated compounds are over 9 times more potent than resveratrol in inhibiting IFN-y production by human PBMC (Table 2).
Table 1. Effect of the novel compounds and resveratrol against human PBMC
proliferation.
Compound ICSO (~,M) 13 2.97 37 5.62 38 9.91 39 7.36 _ Resveratrol > 50 Table 2. Effect of the novel compounds and resveratrol on IFN-y production by human PBMC
Compound IFNy ICso (~M) 13 2.55 37 3.80 38 4.29 39 4.16 Resveratrol ~ 39.2 (b).
Effect on human keratinocyte proliferation Human keratinocytes were cultured in the presence of IFN-y and titrated concentrations of drug or the vehicle. The MTT assay was performed after 48 hours of culture.
Results: Compound 13 had an ICSO of 4.3 ~M compared to that of resveratrol of >50, indicating compound 13 is more than 10 times potent than is resveratrol (Table 3).
Table 3. Effect of the novel compound 13 and resveratrol on human keratinocyte proliferation.
Compound ICso (N.M) 13 4.3 resveratrol > 50 (c).
Effect on migration of human white blood cells (WBC) induced by leukotriene Experiment:WBC collected from donors was mixed with equal volume of 3% dextran (in O.15M
NaCI). The red blood cells were sedimented (45 minutes, room temperature) and removed. Any remaining red blood cells in the plasma were removed by adding 150mM of Tris-NH4Cl. The leukocyte-rich plasma was washed twice in Hanks balanced salts solution containing 20 mM HEPES.
The WBC was then transferred to RPMI-1640 medium and adjusted to a density of 5x10' cellslml.
An agarose plate assay system (Nelson et al. 1978)was used to measure the WBC
migration. Briefly, a 0.8% agarose solution was prepared with complete RPMI-1640 cell culture medium. About 3.5 ml of this agarose solution was transferred to a glass slide before it solidified. Wells were made on the slide in a 3~e6 array fashion (~2 mm, inter-well distance 3mm) once the agarose had solidified. LTB4 was dissolved in anhydrous ethanol to 104 ng/ml and further diluted with the RPMI-1640 medium to 10 ng/ml for the test. Compound 39 was dissolved in DMSO, diluted with RPMI-1640 to 103 p,g/ml and tested at the following concentrations:100, 10, 1, 0.1 and 0.01 p,g/ml.
Ten microlitres of cell suspension with different concentrations of compound 39 was added to each well of the center row of the three rows of wells. The same volume of LTBQ in RPMI-1640 medium or the medium alone was added to wells in the other rows and served as controls. After 5 h incubation (5% COa, 37°C) the test slides were fixed with 100% methanol (30 min) and dried at 4°C
(overnight). The slides were then examined microscopically. The migration index was defined as the average distances that cells migrated towards the positive LTBd well divided by that of spontaneous migration. The percentage migration was compared between treatment and the non-drug control. The dose-effect relationship was determined by plotting the percentage chemotaxis vs concentration for ICso values.
Results: Compound 39 inhibited the migration of WBC towards LTB4 in a dose-dependent manner (Table 4).
Table 4. Effect of Compound 39 on human white blood cell migration towards LTB4.
Concentration (pM) % Migration 40 13.075.8 8 58.464.3 1.6 83.8515.9 -0.32 88.4618.6 Conclusion:
Compound showed potent inhibitory activity against WBC
migration induced by leukotriene B4, a mediator that plays important role in inflammation, including the auto-immune response.
(d). The effect on vascular endothelial growth factor (VEGF) protein expression Experiment: Compound 39 was dissolved in DMSO, diluted with keratinocyte-serum-free medium (KC-SFM) to 103 p,g/ml, further diluted with the culture medium and tested at the following concentrations: 10, 1, 0.1 and 0.01 p,g/ml. Prime cultures of keratinocytes were obtained from a Z5 commercial source and maintained with KC-SFM at a cell density of 106/ml.
In the test, cells were cultured in 24-well plates and incubated at 37°C in 5% COZ first for 4 h, and then treated with rhTGF-a (final concentration 100 ng/ml) and the test compound at different concentrations (0.01-10 p,g/ml).
Medium without test compound was the negative control. The culture supernatant from each well was separately collected after an additional 24 h incubation and centrifuged at 2000rpm for 5 minutes before measuring the VEGF concentration. VEGF concentration in the supernatant in each well was calculated based on measurements taken using an ELISA kit, according to the manufacturer's instructions.
Results: Compound 39 showed a dose-dependent effect on the VEGF concentration in the cell supernatant of keratinocytes induced by rhTGF-a after 24-h treatment. This effect increased substantially and the protein concentration decreased 100% when compound 39 concentration increased to 40 M (Table 5).
Table 5. Effect of Compound 39 on VEGF expression of human keratinocytes induced by rhTGF-cc.
Concentration (pM)VEGF(pg/ml) 8 33.61.8 1.6 34.42.0 0 3 8.92.8 Conclusion:
Compound had a significant inhibitory effect on VEGF
expression in human keratinocytes.
(e) In vivo efficacy in endotoxemia mouse model.
Experiment: Test compounds were dissolved and formulated in 50% PEG-400 in water. Female Balb/c mice (~20g) were first injected separately intraperitoneally (IP) with 25 mg/kg of each test compound, then challenged by injection with 40 mglkg lipopolysaccharide (LPS) (IP) 30 minutes later. One drug injection with 12.5 mg/kg of test compound was done at the same time as (LPS
challenge and two subsequent sequential injections at 30 minutes intervals.
Positive control of dexamethasone was administered in a similar manner starting at 0.4 mg/kg and subsequently 0.2 mg/kg for three additional injections. Mice were sacrificed and blood collected by cardiac puncture 150 minutes after LPS challenge. The serum TNF-a levels were determined by ELISA. Each test group was comprised of six mice. Group of mice injected with the vehicle alone was used as negative control.
Results: Compound 37 and 39 decreased significantly (P<0.05) TNF-a levels in mice blood induced by LPS (Table 6).
Table 6. Effect of the novel compounds, 37 and 39 on TNF-a levels induced by LPS in a mouse model.
Compound TNF-a (pg/mL)P-value 37 638.9273.0 0.03 39 601.6211.9 0.01 Carrier 1126.63 96.4 Dexamethasone 281.367.2 0.0004 ZS P-values calculated with Student's t-test (unpaired, two-tailed) Conclusions:The fluorinated compounds, compound 37 and 39 significantly decreased levels of TNF-a that modulate a broad range of activities in mice, resulting in reduced inflammatory reactions in animals., (f). Efficacy on TPA induced edema.
Experiment: Three representative compounds, 5-(2-phenylethenyl)-2-i-propyl-1,3-benzenediol, a s previously reported, a closely related stilbene derivative (WO 0142231) and compound 39, a novel compound of the current invention, were assayed against the edema on female mice (Balblc) aged 10-12 weeks, using 0.01% Calcitriol (a commercial standard) as a positive control. Phorbol-12-myristate-13-acetate (TPA) was used as the edema inducer. TPA and the test compounds were all dissolved in 100% ethanol and 20 p,l applied on the right ear of the mouse with six mice per group. The TPA
concentration used was 0.01 % (w/v). Ear thickness was measured 6 hours after TPA treatment to determine if edema was decreased. In each experiment replicated groups of TPA
treated mice were treated with either 5-(2-phenylethenyl)-2-i-propyl-1,3-benzenediol, Calcitriol, compound 39 or only ethanol, and the levels of inhibition was obtained by measuring the thickness of the ear and expressing the difference in thiclmess of the treated ear from that of the ethanol treated ear, as a percentage.
Results: The fluorinated compound reduces the edema significantly. With one of H atoms of the previously reported stilbene, 5-(2-phenylethenyl)-2-i-propyl-1,3-benzenediol, replaced by a F to the novel compound 39 of the current invention, the inhibition of edema is increased from 8% to 85%
while inhibition of Calcitriol was 31%, demonstrating the surprisingly high levels of activity of the novel compound 39 of the current invention.
Table 6. Anti-inflammatory activity of stilbene compound after a single topical administration in the TPA-induced ear edema model Treatment % edema inhibition TPA(0.01%) +

5-(2-phenylethenyl)-2-i-propyl-1, 8.0 3-benzenediol (0.3%) TPA(0.01%) +

Compound 39 (0.3%) 85.2 TPA(0.01%) +

Calcitriol (0.01%) 31.2

Claims (29)

1. A compound of formula I, or a salt thereof wherein R1 is selected from the group consisting of unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, or COR9;
R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl;
R4, R5, R6, R7 and R8 are not H simultaneously and are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)2N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic, or a heterocyclic group; with the proviso that R6 is not hydroxy or alkyoxy group when R1 is an unsaturated group comprising of 1-3 isoprene unit(s);
R9 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl, or NR10R11, or OR10;
R10 and R11 are selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl;
R12 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl; wherein the configuration of the double bond of the compound of formula I is E or Z.
2. The compound of claim 1, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic, or a heterocyclic group provided that one or more than one of R4, R5, R6, R7 and R8 is F.
3. The compound of claim 1, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, COR9, and OR12, provided that one, or more than one of R3, R4, R5, R6 and R7 is COR9.
4. The compound of claim 3, wherein R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, or acyl;
5. The compound of claim 4, wherein R2 and R3 are independently selected from the group consisting of H, methyl, or acetate;
6. The compound of claim 2, wherein R1 is selected from unsubstituted or substituted alkyl of 1 to 14 carbons; R2 and R3 are independently each selected from the group consisting of H, unsubstituted or substituted alkyl or acyl;
7. The compound of claim 6, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H and F, provided that one, or more than one of R4, R5, R6, R7 and R8 is F.
8. The compound of claim 6, wherein R1 is isopropyl; R2 and R3 are independently each selected from the group consisting of H, methyl or acetate;
9. The compound of claim 1, wherein the compound is selected from the group consisting of:
4-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
4-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethane;
5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3,5-dimethoxyphenyl)ethane;
5-[2-(3,5-Dihydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-[2,5-Dimethoxy-4-(2-phenylethenyl)phenyl]-1-phenylmethanol;
2,5-Dimethoxy-4-(2-phenylethenyl) benzaldehyde;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-phenylethene;
5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol;
1-(4-Bromo-3,5-dimethoxyphenyl)-2-phenylethene;
2-Bromo-5-(2-phenylethenyl)-1,3-benzenediol;
1-(3,5-Dimethoxy-4-ethylphenyl)-2-phenylethene;
2-Ethyl-5-(2-phenylethenyl)-1,3-benzenediol;
2-(3,5-Dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-fluorophenyl)ethane;
2-(3,5-Difluorophenyl)-1-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,4-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,6-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,4,6-trifluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,3,4,5,6-pentafluorophenyl)ethane;
5-[2-(2-Fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(3-Fluorophenyl)ethenyl]-2-i-propylphenyl-1,3-diol;
5-[2-(4-Fluorophenyl)ethenyl]-2-i-propylphenyl-1,3-diol;
5-[2-(3,5-Difluorophenyl)ethenyl]-2-i-propylphenyl-1,3-diol;
5-[2-(2,4-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(2,6-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
2-i-Propyl-5-[2-(2,4,6-trifluorophenyl)ethenyl]-1,3-benzenediol;
5-[2-(2,3,4,5,6-Pentafluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
10. A pharmaceutical composition comprising: a compound of formula I, or a salt thereof wherein R1 is selected from the group consisting of unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, or COR9;
R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl;
R4, R5, R6, R7 and R8 are not H simultaneously and are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic or a heterocyclic group; with the proviso that R6 is not hydroxy or alkyoxy group when R1 is an unsaturated group comprising of 1-3 isoprene unit(s);
R9 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl, or NR10R11, or OR10;
R10 and R11 are selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl;
R12 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl;wherein the configuration of the double bond of the compound of formula I is E or Z, and a pharmaceutically acceptable diluent or carrier.
11. The composition of claim 10, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)2N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic or a heterocyclic group provided that one or more than one of R4, R5, R6, R7 and R8 is F.
12. The composition of claim 10, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, COR9, and OR12, provided that one, or more than one of R3, R4, R5, R6 and R7 is COR9.
13. The composition of claim 12, wherein R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, or acyl;
14. The composition of claim 13, wherein R2 and R3 are independently selected from the group consisting of H, methyl, or acetate;
15. The composition of claim 11, wherein R1 is selected from unsubstituted or substituted alkyl of 1 to 14 carbons; R2 and R3 are independently each selected from the group consisting of H, unsubstituted or substituted alkyl or acyl;
16. The composition of claim 15, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H and F, provided that one, or more than one of R4, R5, R6, R7 and R8 is F.
17. The composition of claim 15, wherein R1 is isopropyl; R2 and R3 are independently each selected from the group consisting of H, methyl or acetate;
18. The composition of claim 10, wherein the compound is selected from the group consisting of:
4-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
4-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethane;
5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3,5-dimethoxyphenyl)ethane;
5-[2-(3,5-Dihydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-[2,5-Dimethoxy-4-(2-phenylethenyl)phenyl]-1-phenylmethanol;
2,5-Dimethoxy-4-(2-phenylethenyl) benzaldehyde;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-phenylethene;
5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol;
1-(4-Bromo-3,5-dimethoxyphenyl)-2-phenylethene;
2-Bromo-5-(2-phenylethenyl)-1,3-benzenediol;
1-(3,5-Dimethoxy-4-ethylphenyl)-2-phenylethene;
2-Ethyl-5-(2-phenylethenyl)-1,3-benzenediol;
2-(3,5-Dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-fluorophenyl)ethane;
2-(3,5-Difluorophenyl)-1-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,4-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,6-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,4,6-trifluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,3,4,5,6-pentafluorophenyl)ethane;
5-[2-(2-Fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(3-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(4-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(3,5-Difluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(2,4-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(2,6-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
2-i-Propyl-5-[2-(2,4,6-trifluorophenyl)ethenyl]-1,3-benzenediol;
5-[2-(2,3,4,5,6-Pentafluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
19. A use of a compound of formula I, wherein R1 is selected from the group consisting of unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, or COR9;
R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl;
R4, R5, R6, R7 and R8 are not H simultaneously and are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)2N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic, or a heterocyclic group; with the proviso that R6 is not hydroxy or alkyoxy group when R1 is an unsaturated group comprising of 1-3 isoprene unit(s);
R9 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl, or NR10R11, or OR10;
R10 and R11 are selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl;
R12 is selected from H, unsubstituted or substituted alkyl, cycloalkyl, aryl, aralkyl or acyl; wherein the configuration of the double bond of the compound of formula I is E or Z, in the preparation of a medication for treating a disorder comprising immune, inflammatory or autoimmune diseases.
20. The use according to claim 19, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or aralkyl group, halo, nitro, CN, COR9, NR10R11, S(O)2N R10R11, S(O)n R10, n = 0-2, OR12, a cyclic or a heterocyclic group provided that one or more than one of R4, R5, R6, R7 and R8 is F.
21. The use according to 19, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, COR9, and OR12, provided that one, or more than one of R3, R4, R5, R6 and R7 is COR9.
22. The use according to claim 21, wherein R2 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, or acyl;
23. The use according to claim 22, wherein R2 and R3 are independently selected from the group consisting of H, methyl, or acetate;
24. The use according to claim 20, wherein R1 is selected from unsubstituted or substituted alkyl of 1 to 14 carbons; R2 and R3 are independently each selected from the group consisting of H, unsubstituted or substituted alkyl or acyl;
25. The use according to claim 24, wherein R4, R5, R6, R7 and R8 are independently selected from the group consisting of H and F, provided that one, or more than one of R4, R5, R6, R7 and R8 is F.
26. The use according to claim 24, wherein R1 is isopropyl; R2 and R3 are independently each selected from the group consisting of H, methyl or acetate;
27. The use according to claim 19, wherein the compound is selected from the group consisting of:
4-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dimethoxy-4-i-propylphenyl)ethenyl]benzoic acid;
4-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
3-[2-(3.5-Dihydroxy-4-i-propylphenyl)ethenyl]benzoic acid;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-methoxyphenyl)ethane;
5-[2-(4-Hydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3,5-dimethoxyphenyl)ethane;
5-[2-(3,5-Dihydroxyphenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
1-[2,5-Dimethoxy-4-(2-phenylethenyl)phenyl]-1-phenylmethanol;
2,5-Dimethoxy-4-(2-phenylethenyl) benzaldehyde;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-phenylethene;
5-(2-Phenylethenyl)-2-i-propyl-1,3-benzenediol;
1-(4-Bromo-3,5-dimethoxyphenyl)-2-phenylethene;
2-Bromo-5-(2-phenylethenyl)-1,3-benzenediol;
1-(3,5-Dimethoxy-4-ethylphenyl)-2-phenylethene;
2-Ethyl-5-(2-phenylethenyl)-1,3-benzenediol;
2-(3,5-Dimethoxy-4-i-propylphenyl)-1-(2-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(3-fluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(4-fluorophenyl)ethane;
2-(3,5-Difluorophenyl)-1-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,4-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(2,6-Difluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,4,6-trifluorophenyl)ethane;
1-(3,5-Dimethoxy-4-i-propylphenyl)-2-(2,3,4,5,6-pentafluorophenyl)ethane;
5-[2-(2-Fluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(3-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(4-Fluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(3,5-Difluorophenyl)ethenyl]-2- i-propylphenyl-1,3-diol;
5-[2-(2,4-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
5-[2-(2,6-Difluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
2-i-Propyl-5-[2-(2,4,6-trifluorophenyl)ethenyl]-1,3-benzenediol;
5-[2-(2,3,4,5,6-Pentafluorophenyl)ethenyl]-2-i-propyl-1,3-benzenediol;
28. The method for treating a disorder comprising immune, inflammatory or autoimmune diseases in mammals comprising administering to a mammal so afflicted an effective amount of a compound of Formula I as defined in claim 1 or a salt thereof.
29. The method for treating a disorder comprising immune, inflammatory or autoimmune diseases in mammals comprising administering to a mammal so afflicted an effective amount of a compound according to claim 2-9 or a salt thereof.
CA002501663A 2002-10-01 2003-09-30 Stilbene derivatives having an immune-modulating activity Abandoned CA2501663A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41463202P 2002-10-01 2002-10-01
US41463302P 2002-10-01 2002-10-01
US60/414,632 2002-10-01
US60/414,633 2002-10-01
PCT/CA2003/001497 WO2004031117A1 (en) 2000-10-06 2003-09-30 Novel bioactive diphenyl ethene compounds and their therapeutic applications

Publications (1)

Publication Number Publication Date
CA2501663A1 true CA2501663A1 (en) 2004-04-15

Family

ID=34278219

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501663A Abandoned CA2501663A1 (en) 2002-10-01 2003-09-30 Stilbene derivatives having an immune-modulating activity

Country Status (7)

Country Link
EP (1) EP1554236A1 (en)
JP (1) JP2006508930A (en)
KR (1) KR20050062581A (en)
CN (1) CN1688535B (en)
AU (1) AU2003271470B2 (en)
CA (1) CA2501663A1 (en)
WO (1) WO2004031117A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868047B2 (en) 1999-12-06 2011-01-11 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100836207B1 (en) 2001-01-18 2008-06-09 웰리켐 바이오 테크 인크. Novel 1,2-diphenylethene derivatives for treatment of immune diseases
GB2411353A (en) * 2004-02-25 2005-08-31 Univ Hertfordshire Resveratrol Analogues
FR2898124B1 (en) * 2006-03-03 2008-09-12 Centre Nat Rech Scient RESENDATOL DERIVATIVE WITH LONG HYDROXYLATED CHAIN USEFUL AS NEUROTROPHIC
CN101544591B (en) * 2009-05-06 2013-07-10 河北科技大学 (E)-substituted styrene compound and preparation method thereof
CN102372627B (en) * 2010-08-18 2015-05-27 中国医学科学院医药生物技术研究所 Preparation method of cajanin and substance with similar structure
CN102675061B (en) * 2011-10-31 2016-01-20 合肥市济泉医药科技有限公司 The ether derivant of trans-resveratrol and medical use
CN102675099A (en) * 2011-10-31 2012-09-19 栗艳艳 Ester derivative of high veratryl alcohol and medical treatment application
CN102675060A (en) * 2011-10-31 2012-09-19 栗艳艳 Ether derivatives of phytoalxeni and medical uses thereof
CN103172512B (en) * 2011-12-23 2016-08-03 中国医学科学院医药生物技术研究所 One group of cajanin structurally similar compounds, preparation method and application
CN103483158B (en) * 2013-10-14 2016-06-08 武汉英纳氏药业有限公司 A kind of diphenyl ethane derivative and application thereof
WO2019063002A1 (en) * 2017-09-30 2019-04-04 北京文丰天济医药科技有限公司 Crystal form of benvitimod, and use thereof and preparation method therefor
KR20200087786A (en) 2017-11-10 2020-07-21 더마반트 사이언시즈 게엠베하 Method of manufacturing tapinarov
CN110314153A (en) * 2018-03-29 2019-10-11 中国科学院上海药物研究所 Diphenylethylene compounds treat ischemic disease and the purposes to anti-inflammatory response
CN111217681A (en) * 2020-02-10 2020-06-02 福州百草堂医药科技有限公司 Anti-inflammatory compounds and uses thereof
WO2021236709A1 (en) 2020-05-19 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of tapinarof
CN113072488A (en) * 2021-03-30 2021-07-06 广东工业大学 Styrene derivative and synthesis method and application thereof
CN116350609A (en) * 2021-12-28 2023-06-30 上海泽德曼医药科技有限公司 Compounds for inhibiting vascular endothelial growth and uses thereof
CN115536497A (en) * 2022-11-23 2022-12-30 化学与精细化工广东省实验室 Synthesis method of (E) -3,5-dihydroxy-4-isopropyl stilbene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1072330A (en) * 1996-09-03 1998-03-17 Kansai Kouso Kk Tyrosinase activity inhibitor and cosmetic
JP4880847B2 (en) * 1999-12-06 2012-02-22 ウェリケム，バイオテック インコーポレーテッド Anti-inflammatory and psoriasis treatments and protein kinase inhibition with hydroxylstilbene and novel stilbene derivatives and analogs
EP1435894A4 (en) * 2001-07-23 2005-07-06 Galileo Pharmaceuticals Inc Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868047B2 (en) 1999-12-06 2011-01-11 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Also Published As

Publication number Publication date
CN1688535A (en) 2005-10-26
JP2006508930A (en) 2006-03-16
WO2004031117A1 (en) 2004-04-15
AU2003271470A1 (en) 2004-04-23
KR20050062581A (en) 2005-06-23
EP1554236A1 (en) 2005-07-20
CN1688535B (en) 2011-11-09
AU2003271470B2 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
AU2003271470B2 (en) Novel bioactive diphenyl ethene compounds and their therapeutic applications
US7868047B2 (en) Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
JPH10504836A (en) Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for analgesia
JP2014055134A (en) Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
MX2012005281A (en) Gpbp inhibition using q2 peptidomimetics.
CA2433417C (en) Novel 1,2-diphenylethene derivatives for treatment of immune diseases
JPH0255430B2 (en)
KR20170090497A (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
AU2002226225A1 (en) Novel 1,2-diphenylethene derivatives for treatment of immune diseases
JP2796876B2 (en) Substituted pyrrolidine compounds and pharmaceutical compositions
US20080255245A1 (en) Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues
Perchonock et al. Synthesis and structure-activity relationship studies of a series of 5-aryl-4, 6-dithianonanedioic acids and related compounds: a novel class of leukotriene antagonists
EP1742903B1 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
EP0515777A1 (en) PLA2 inhibitors
KR100830541B1 (en) Novel Chalcone Derivatives which Inhibit the IL-5 Activity
WO2021042411A1 (en) Akr1c3 inhibitor or pharmaceutically acceptable salt of same, preparation method for same, and uses thereof
KR20120122705A (en) Imidazole-based Alkaloid Derivatives for Inhibition of Angiogenesis and anti-oxidant activity, and Methods for Preparing them
NZ232004A (en) Naphthalene derivatives and pharmaceutical preparations
CA2980221C (en) Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof
JP3107613B2 (en) Naphthalene derivative
KR101774224B1 (en) Synthetic method for rugchalcone A, B and their derivatives and their anti-inflammatory use
JPH03163042A (en) Chalcone derivative
CN115485259A (en) Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof
KR101783199B1 (en) Synthetic method for piceatannol derivatives and pharmaceutical compounds containing the piceatannol derivatives
NO853694L (en) VINYLTETRAZOLYLPHENYL DERIVATIVES, PREPARATION AND USE THEREOF.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued